ASTRAZENECA PLC Form SC 13G/A February 13, 2004

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

Under the Securities Exchange Act of 1934

(Amendment No. 2) *

AstraZeneca plc (Name of Issuer)

American Depositary Shares, representing Ordinary Shares (Title of Class of Securities)

046353108 (CUSIP Number)

December 31, 2003 (Date of Event Which Requires Filing of this Statement)

heck the appropriate box to designate the rule pursuant to which this chedule is filed:

X] Rule 13d-1(b)

| Rule 13d-1(c)

] Rule 13d-1(d)

The remainder of this cover page shall be filled out for a reporting erson's initial filing on this form with respect to the subject class f securities, and for any subsequent amendment containing information hich would alter the disclosures provided in a prior cover page.

he information required in the remainder of this cover page shall not e deemed to be "filed" for the purpose of Section 18 of the Securities xchange Act of 1934 ("Act") or otherwise subject to the liabilities of hat section of the Act but shall be subject to all other provisions of he Act (however, see the Notes).

USIP: 046353108 Page 1 of 5 page> NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) Capital Research and Management Company 95-1411037 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS) (a) (b) SEC USE ONLY 3 CITIZENSHIP OR PLACE OF ORGANIZATION Delaware 5 SOLE VOTING POWER NONE SHARED VOTING POWER NUMBER OF SHARES NONE BENEFICIALL Y OWNED BY 7 SOLE DISPOSITIVE POWER EACH REPORTING 96,245,920 PERSON WITH: SHARED DISPOSITIVE POWER NONE AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 96,245,920 Beneficial ownership disclaimed pursuant to Rule 13d-4 10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS) 11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 5.7% 12 TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)

ΙA

USIP: 046353108 Page 2 of 5

page>

SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549

Schedule 13G Under the Securities Exchange Act of 1934

mendment No. 2

- tem 1(a) Name of Issuer:
 AstraZeneca plc
- tem 1(b) Address of Issuer's Principal Executive Offices:
 15 Stanhope Gate
 London W1Y 6LN
 England
- tem 2(b) Address of Principal Business Office or, if none,
 Residence:
 333 South Hope Street
 Los Angeles, CA 90071
- tem 2(c) Citizenship: N/A
- tem 2(d) Title of Class of Securities:

 American Depositary Shares, representing Ordinary Shares
- tem 2(e) CUSIP Number: 046353108
- tem 4 Ownership

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item $1. \,$

See page 2

- (a) Amount beneficially owned:
- (b) Percent of class:
- (c) Number of shares as to which the person has:
- (i) Sole power to vote or to direct the vote:
- (ii) Shared power to vote or to direct the vote:
- (iii) Sole power to dispose or to direct the disposition of:
- (iv) Shared power to dispose or to direct the disposition of:

USIP: 046353108 Page 3 of 5

page>

Capital Research and Management Company, an investment adviser registered under Section 203 of the Investment Advisers Act of 1940 is deemed to be the beneficial owner of 96,245,920 shares or 5.7% of the 1,701,566,214 shares of Ordinary Shares, including American Depositary Shares, believed to be outstanding as a result of acting as investment adviser to various investment companies registered under Section 8 of the Investment Company Act of 1940.

Shares reported by Capital Research and Management Company include 20,834,920 American Depositary Shares, representing 20,834,920 shares of the Ordinary Shares.

- tem 5 Ownership of Five Percent or Less of a Class. If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: []
- tem 7 Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.: N/A
- tem 8 Identification and Classification of Members of the Group: $\ensuremath{\mathrm{N/A}}$
- tem 9 Notice of Dissolution of Group: N/A
- tem 10 Certification

By signing below, I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

Signature

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: February 9, 2004

Signature: *Paul G. Haaga, Jr.

Name/Title: Paul G. Haaga, Jr., Executive Vice

President

Capital Research and Management Company

USIP: 046353108 Page 4 of 5

page>

*By /s/ James P. Ryan James P. Ryan Attorney-in-fact

Signed pursuant to a Power of Attorney dated January 14, 2004 included as an Exhibit to Schedule 13G filed with the Securities and Exchange Commission by Capital Research and Management Company on February 6, 2004 with respect to Air Products and Chemicals, Incorporated

USIP: 046353108 Page 5 of 5

page>